The FDA approved Attruby, a drug that targets the transthyretin protein and stabilizes it to prevent additional misfolding and deposition within cardiac tissues. This mechanism treats the underlying cause of the disease, making it an interventional approach that both slows disease progression and improves survival.Data from clinical trials showed that Attruby significantly reduced hospitalization and death associated…